DSpace Collection: LIM/31 - Laboratório de Genética e Hematologia MolecularLIM/31 - Laboratório de Genética e Hematologia Molecularhttps://observatorio.fm.usp.br/handle/OPI/37192024-03-28T13:54:14Z2024-03-28T13:54:14ZVisceral Leishmaniasis Revealing Undiagnosed Inborn Errors of ImmunityCARVALHO, Daniel GleisonVASCONCELOS, Dewton de MoraesSANTOS, Andreia Cristiane RangelLINDOSO, Jose Angelo Laulettahttps://observatorio.fm.usp.br/handle/OPI/576992024-03-08T06:09:18Z2023-01-01T00:00:00ZTitle: Visceral Leishmaniasis Revealing Undiagnosed Inborn Errors of Immunity
Authors: CARVALHO, Daniel Gleison; VASCONCELOS, Dewton de Moraes; SANTOS, Andreia Cristiane Rangel; LINDOSO, Jose Angelo Lauletta
Abstract: Visceral Leishmaniasis (VL) is a potentially fatal disease and may be associated with primary or acquired immunodeficiencies. There are few reports, in the literature, of inborn errors of immunity. Here, we report two cases of VL as a marker of inborn errors of immunity, namely, GATA2 and RAB27A deficiency. Our data suggest that VL patients should be screened for primary immunodeficiency, particularly in cases of VL relapse.2023-01-01T00:00:00ZData mining in acute myeloid leukemia: identification of disease biomarkers, prognostic factors, novel targets, and potential drugsMACHADO-NETO, Joao AgostinhoNASCIMENTO, Mariane Cristina doGARNIQUE, Anali Del Milagro BernabeLIMA, Kelihttps://observatorio.fm.usp.br/handle/OPI/575822024-02-27T06:06:28Z2023-01-01T00:00:00ZTitle: Data mining in acute myeloid leukemia: identification of disease biomarkers, prognostic factors, novel targets, and potential drugs
Authors: MACHADO-NETO, Joao Agostinho; NASCIMENTO, Mariane Cristina do; GARNIQUE, Anali Del Milagro Bernabe; LIMA, Keli2023-01-01T00:00:00ZEvaluation of Dengue, Zika virus, and Chikungunya virus transmission by blood components in recipients of haematopoietic stem cell transplantationOLIVEIRA, Fernando Nivaldo deFERREIRA, Suzete CleusaNISHIYA, Anna ShokoMENDRONE-JUNIOR, AlfredoBATISTA, Marjorie VieiraROCHA, VandersonCOSTA, Silvia Figueiredohttps://observatorio.fm.usp.br/handle/OPI/573562024-03-02T06:06:56Z2023-01-01T00:00:00ZTitle: Evaluation of Dengue, Zika virus, and Chikungunya virus transmission by blood components in recipients of haematopoietic stem cell transplantation
Authors: OLIVEIRA, Fernando Nivaldo de; FERREIRA, Suzete Cleusa; NISHIYA, Anna Shoko; MENDRONE-JUNIOR, Alfredo; BATISTA, Marjorie Vieira; ROCHA, Vanderson; COSTA, Silvia Figueiredo
Abstract: BackgroundBrazil has a high prevalence of arboviruses, especially Dengue (DENV), Zika (ZKV), and Chikungunya (CHKV). ObjectivesTo study the risk of DENV, ZKV, and CHKV transmission by blood components in the haematopoietic stem cell transplantation (HSCT) population. MethodsProspective cohort of HSCT recipients and donors performed at the Hospital das Clinicas da FMUSP, Sao Paulo-Brazil. Patients were evaluated by serology and RT-PCR for DENV, ZKV, and CHKV pre-transplantation and once a week until neutrophil grafting. In positive cases (positive RT-PCR and/or serology conversion), an investigation was carried out on the blood components that the patient received to evaluate the possibility of it being transfusion transmitted. ResultsA total of 93 patients were included during the study period. The mean age was 52 years with a predominance of males (56.9%). We considered five (5.3%) DENV cases positive by seroconversion in our study. One patient had IgM seroconversion and the other four presented IgG seroconversion to DENV. In the investigation of the blood components, 145 individual samples were analysed. None of the investigated blood components showed a positive RT-PCR. ConclusionWe observed a low prevalence of DENV, ZKV, and CHKV in HSCT donors and recipients by serology and RT-PCR, and no case of blood transfusion transmission by RT-PCR.2023-01-01T00:00:00ZMulticenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical TrialsLIN, ChenyuSCHWARZBACH, AurelieSANZ, JaimeMONTESINOS, PauSTIFF, PatrickPARIKHA, SuhagBRUNSTEIN, ClaudioCUTLER, CoreyLINDEMANS, Caroline A.HANNA, RabiKOH, Liang PiuJAGASIA, Madan H.VALCARCEL, DavidMAZIARZ, Richard T.KEATING, Amy K.HWANG, William Y. K.REZVANI, Andrew R.KARRAS, Nicole A.FERNANDES, Juliana F.ROCHA, VandersonBADELL, IsabelRAM, RonSCHILLER, Gary J.VOLODIN, LeonidWALTERS, Mark C.HAMERSCHLAK, NelsonCILLONI, DanielaFRANKFURT, OlgaMCGUIRK, Joseph P.KURTZBERG, JoanneSANZ, GuillermoSIMANTOV, RonitHORWITZ, Mitchell E.https://observatorio.fm.usp.br/handle/OPI/573532024-03-06T06:07:14Z2023-01-01T00:00:00ZTitle: Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
Authors: LIN, Chenyu; SCHWARZBACH, Aurelie; SANZ, Jaime; MONTESINOS, Pau; STIFF, Patrick; PARIKHA, Suhag; BRUNSTEIN, Claudio; CUTLER, Corey; LINDEMANS, Caroline A.; HANNA, Rabi; KOH, Liang Piu; JAGASIA, Madan H.; VALCARCEL, David; MAZIARZ, Richard T.; KEATING, Amy K.; HWANG, William Y. K.; REZVANI, Andrew R.; KARRAS, Nicole A.; FERNANDES, Juliana F.; ROCHA, Vanderson; BADELL, Isabel; RAM, Ron; SCHILLER, Gary J.; VOLODIN, Leonid; WALTERS, Mark C.; HAMERSCHLAK, Nelson; CILLONI, Daniela; FRANKFURT, Olga; MCGUIRK, Joseph P.; KURTZBERG, Joanne; SANZ, Guillermo; SIMANTOV, Ronit; HORWITZ, Mitchell E.
Abstract: Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has dem-onstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early benefits of omidubicel have been established, long-term outcomes remain unknown. We report on a planned pooled analysis of 5 multicenter clinical trials including 105 patients with hematologic malignancies or sickle cell hemoglobinopathy who underwent omidubicel transplantation at 26 academic transplantation centers worldwide. With a median follow-up of 22 months (range, .3 to 122 months), the 3-year estimated overall survival and disease-free survival were 62.7% and 56.4%, respectively. With up to 10 years of follow-up, omidubicel showed durable trilineage hematopoiesis. Serial quantitative assessments of CD3(+), CD4(+), CD8(+), CD19(+), CD116(+)CD56(+), and CD123(+) immune subsets revealed median counts remaining within normal ranges through up to 8 years of follow-up. Secondary graft failure occurred in 5 patients (5%) in the first year, with no late cases reported. One case of donor-derived myeloid neoplasm was reported at 40 months post-transplantation. This was also observed in a control arm patient who received only unmanipulated UCB. Overall, omidubicel demonstrated stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up. (c) 2023 The American Society for Transplantation and Cellular Therapy.2023-01-01T00:00:00Z